Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methdilazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.80 |
| ▸ | DRD1 | P21728 | 3/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.80 |
| ▸ | DRD3 | P35462 | 3/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.80 |
| ▸ | HTR2A | P28223 | 2/20 | 0.80 |
| ▸ | HTR2B | P41595 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methdilazine SCHEMBL121507 | 0.97 | CYP2D6 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL29415150 | 0.97 | CYP2D6 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL1518885 | 0.97 | CYP2D6 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL30903921 | 0.96 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL28086451 | 0.96 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL211226 | 0.96 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL1651268 | 0.92 | CHRM2 (0.95) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| SCHEMBL14675038 | 0.90 | CYP2D6 (0.86) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL17746928 | 0.89 | CHRM2 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL29436812 | 0.89 | CHRM2 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2016-12-15 | — | — | US | disclosed |
| EP-2949212-A1 | USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS | Fred Hutchinson Cancer Research Center (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2015-06-18 | — | — | US | disclosed |
| US-8822535-B2 | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-09-02 | — | — | US | disclosed |
| CN-1901795-B | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES | 2014-03-26 | — | — | CN | disclosed |
| EP-1879599-B1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | HUTCHINSON FRED CANCER RES (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120052479-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | ROTH MARK B (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2363022-A2 | Use of oxygen antagonists for the therapeutic treatment of mammals | Fred Hutchinson Cancer Research Center (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7993681-B2 | Exposing isolated tissue to an oxygen antagonist, e.g., a chalcogenide reducing agent, hydrogen sulfide; controlling cellular metabolism by binding to cytochrome oxidase and inhibiting or reducing oxidative phosphorylation activity; nontoxic; preservation; tranplantations; transfusions; transportation | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | BCL2, BAX, HSF1 | HRH1 2493/4885CYP2D6 2254/4885CYP1A2 3289/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | HRH1 2287/4885CYP2D6 2282/4885CYP1A2 1322/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885CYP2D6 3677/4885CYP1A2 4132/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | HRH1 2221/4885CYP2D6 4474/4885CYP1A2 3826/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | HRH1 3316/4885CYP2D6 4288/4885CYP1A2 3384/4885 |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885CYP2D6 3677/4885CYP1A2 4132/4885 |
| US-20120052479-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | HIF1A, HIF1AN, PYGL | HRH1 2287/4885CYP2D6 2282/4885CYP1A2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.